NASDAQ:TNDM - Tandem Diabetes Care Stock Price, Forecast & News

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Shares of Tandem Diabetes Care reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

Tandem Diabetes Care Inc (NASDAQ:TNDM) posted its quarterly earnings data on Monday, February, 24th. The medical device company reported $0.04 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.03) by $0.07. The medical device company earned $108.40 million during the quarter, compared to analyst estimates of $109.22 million. Tandem Diabetes Care had a negative return on equity of 9.44% and a negative net margin of 7.19%. The business's revenue for the quarter was up 42.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.02 EPS. View Tandem Diabetes Care's Earnings History.

Tandem Diabetes Care issued an update on its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $450-465 million, compared to the consensus revenue estimate of $444.62 million.

14 equities research analysts have issued 12 month target prices for Tandem Diabetes Care's stock. Their forecasts range from $65.00 to $100.00. On average, they anticipate Tandem Diabetes Care's share price to reach $79.79 in the next twelve months. This suggests that the stock has a possible downside of 8.1%. View Analyst Price Targets for Tandem Diabetes Care.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tandem Diabetes Care.

News stories about TNDM stock have trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Tandem Diabetes Care earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media headlines about the medical device company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Tandem Diabetes Care.

Tandem Diabetes Care saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 6,970,000 shares, an increase of 17.7% from the December 31st total of 5,920,000 shares. Based on an average daily volume of 1,460,000 shares, the short-interest ratio is presently 4.8 days. Currently, 12.5% of the company's stock are sold short. View Tandem Diabetes Care's Current Options Chain.

Some companies that are related to Tandem Diabetes Care include Teleflex (TFX), Insulet (PODD), Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), ICU Medical (ICUI), Nevro (NVRO), NuVasive (NUVA), Cantel Medical (CMD), Irhythm Technologies (IRTC) and Glaukos (GKOS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Tesla (TSLA) and Paypal (PYPL).

Tandem Diabetes Care's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (3.97%), Fred Alger Management LLC (2.43%), State Street Corp (2.26%), Delphi Management Partners VIII L.L.C. (1.69%), Eagle Asset Management Inc. (1.67%) and Geode Capital Management LLC (1.49%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Richard P Valencia and Susan Morrison. View Institutional Ownership Trends for Tandem Diabetes Care.

TNDM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Lord Abbett & CO. LLC, Fred Alger Management LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Marshall Wace North America L.P., Driehaus Capital Management LLC and Columbus Circle Investors. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller and Susan Morrison. View Insider Buying and Selling for Tandem Diabetes Care.

TNDM stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Delphi Management Partners VIII L.L.C., Jennison Associates LLC, Perceptive Advisors LLC, UBS Asset Management Americas Inc., J. Goldman & Co LP, Parkman Healthcare Partners LLC and Goldman Sachs Group Inc.. Company insiders that have bought Tandem Diabetes Care stock in the last two years include Dick Allen and Richard P Valencia. View Insider Buying and Selling for Tandem Diabetes Care.

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TNDM stock can currently be purchased for approximately $86.79.

Tandem Diabetes Care has a market capitalization of $5.13 billion and generates $183.87 million in revenue each year. The medical device company earns $-122,610,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Tandem Diabetes Care employs 653 workers across the globe.View Additional Information About Tandem Diabetes Care.

The official website for Tandem Diabetes Care is http://www.tandemdiabetes.com/.

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected]